A twist or pivot on a bent knee, a direct blow to the knee, or wear and tear as an individual gets older can cause Articular Defects or a chondral injury. Articular Defects can be caused by an injury to a ligament, such as the anterior crutiate ligament (ACL). Small pieces of cartilage break down and float around in the joints or close proximity in Articular Defects, causing locking, catching, and swelling. The majority of patients do not have a clear history of a single injury; rather, the injury is the result of a series of minor injuries that occurred over time.
Chondromalacia is a condition that occurs when cartilage is damaged. Articular defects can affect anyone, including children, adults, and the elderly. Treatment for articular defects is determined by the defect’s location and size. In general, defects at the femur’s end are the easiest to treat and result in the best results. Articular defects on the kneecap and tibia are more difficult to treat, and the outcomes aren’t always accurate. The treatment of very deep articular defects that extend all the way down to the bone is dependent on the location and overall diameter of the defect. Microfracture, which relies on the patient’s stem cells, can be used to treat smaller articular defects.
Market Drivers and Restraints for Articular Defects Treatment
Over the forecast period, the rising prevalence and recurrence of osteoarthritis, obesity, metabolic syndrome, and articular defects is expected to be a major factor driving the articular defects treatment market. Obesity and dietary factors, joint loading and injury, and joint shape and alignment are some of the major factors contributing to the increasing prevalence of osteoarthritis, which is one of the major factors resulting in articular defects, according to a survey published by NCBI in 2015. The introduction and addition of new types of methods and devices are some of the other factors driving the global Articular Defects Treatment Market forward.
For example, the European Medicines Agency (EMA) has recommended that a new Advanced Therapy Medicinal Product (ATMP), Spherox, be granted and marketed in the European Union to treat adult patients with symptomatic articular defects in the femoral and patellofemoral joints.
Overview of the Articular Defects Treatment Market
During the forecast period, the global market for articular defect treatment is expected to grow at a moderate rate. A variety of hospitals, orthopaedic clinics, ambulatory surgical centres, and specialty clinics offer a variety of articular defect treatment options. The hospitals and ambulatory surgical centres segments are expected to lead the global Articular Defects Treatment Market during the forecast period among end users in the Articular Defects Treatment Market. Among the procedure types, the microfracture segment is expected to dominate the global Articular Defects Treatment Market, though other procedure types are also used and are suitable for various articular defect conditions.
For List of Key Players and Full Segmentation, Ask for a Sample Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=1697